高级检索

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

人乳头瘤病毒疫苗经济学评价研究进展

王晓瑄 张良文 方亚

王晓瑄, 张良文, 方亚. 人乳头瘤病毒疫苗经济学评价研究进展[J]. 中国公共卫生. doi: 10.11847/zgggws1139192
引用本文: 王晓瑄, 张良文, 方亚. 人乳头瘤病毒疫苗经济学评价研究进展[J]. 中国公共卫生. doi: 10.11847/zgggws1139192
WANG Xiao-xuan, ZHANG Liang-wen, FANG Ya. Progress in economic evaluation of human papillomavirus vaccines[J]. Chinese Journal of Public Health. doi: 10.11847/zgggws1139192
Citation: WANG Xiao-xuan, ZHANG Liang-wen, FANG Ya. Progress in economic evaluation of human papillomavirus vaccines[J]. Chinese Journal of Public Health. doi: 10.11847/zgggws1139192

人乳头瘤病毒疫苗经济学评价研究进展

doi: 10.11847/zgggws1139192
基金项目: 国家自然科学基金(81973144)
详细信息
    作者简介:

    王晓瑄(1999 – ),女,河北沧州人,硕士在读,研究方向:疫苗经济学评价

    通讯作者:

    方亚,E-mail:fangya@xmu.edu.cn

  • 中图分类号: R 186

Progress in economic evaluation of human papillomavirus vaccines

  • 摘要: 人乳头瘤病毒(human papilloma virus, HPV)感染是导致宫颈癌发生的主要病因,其严重危害全球女性的生命健康。HPV疫苗可有效预防HPV感染和降低宫颈癌的发病率,已在世界各国被广泛应用。近年来,许多国家开展了HPV疫苗的经济学评价研究,并着重评价接种HPV疫苗的成本和社会效益。本文通过整理国内外近年来发表的相关文献,对HPV疫苗接种现状及经济学评价研究作一概述,同时阐述数学模型在HPV疫苗经济学评价中的应用,为我国HPV疫苗接种策略的制定和消除宫颈癌提供科学依据。
  • 表  1  HPV疫苗经济学评价研究中不同数学模型应用

    数学模型特点优点缺点
    静态模型 追踪静态易感队列的疾病发展过程,状态转移概率
    不随时间变化,包括进展模型和比例结果模型。
    所用参数较少,构建较为简便,
    可行性高,应用范围广
    研究静态队列,不能测算群体
    免疫效应和疫苗的间接效益
    动态模型 模拟动态队列的疾病发展随时间变化情况,各健康
    状态转移概率随时间改变,考虑个体间的交互作用。
    考虑群体免疫,可以测算性行为
    传播过程,模型更准确、真实
    所需参数较多,部分参数获取较难,构建
    较复杂,可行性较差,预测结果可能不稳定
    混合模型 静态模型和动态模型联合使用,将动力学模型得到的
    结果放入静态模型进行模拟、预测未来发展趋势。
    结合静态模型和动态模型的特点,
    适用范围广,模型更为精准、科学
    模型构建较复杂,所需参数较多,部分
    参数较难获取,可能导致结果偏倚
    下载: 导出CSV
  • [1] Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus - related cancer incidence by gender and anatomic site of infection[J]. International Journal of Cancer, 2015, 136(12): 2752 – 2760. doi: 10.1002/ijc.29082
    [2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209 – 249. doi: 10.3322/caac.21660
    [3] 赫捷. 2018中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2019.
    [4] Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. The Lancet Global Health, 2020, 8(2): E191 – E203. doi: 10.1016/S2214-109X(19)30482-6
    [5] 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8): 761 – 803. doi: 10.3760/cma.j.issn.0253-9624.2019.08.001
    [6] 广东省预防医学会宫颈癌防治专业委员会. 消除子宫颈癌之HPV疫苗应用广东专家共识[J]. 中国医师杂志, 2021, 23(9): 1303 – 1315. doi: 10.3760/cma.j.cn431274-20210819-00911
    [7] 健康厦门行动推进委员会. 健康厦门行动推进委员会关于印发2021 — 2025年厦门市适龄女性“两癌”防治项目实施方案(试行)的通知[EB/OL]. (2022 – 03 – 30)[2022 – 05 – 14].https://hfpc.xm.gov.cn/zfxxgk/ml/09/07/202203/t20220330_2646665.htm.
    [8] 鄂尔多斯市人民政府. 全市适龄女性两癌防治项目实施方案[EB/OL]. (2020 – 12 – 24)[2022 – 05 – 14]. http://www.ordos.gov.cn/ordosml/ordoszf/202012/t20201228_2827928.html.
    [9] 綦小蓉, 边策. 人乳头瘤病毒疫苗接种及研究现状[J]. 实用妇产科杂志, 2016, 32(11): 818 – 822.
    [10] 国家药品监督管理局. 首个国产重组人乳头瘤病毒疫苗获批上市[EB/OL]. (2019 – 12 – 31)[2022 – 03 – 03].https://www.nmpa.gov.cn/yaowen/ypjgyw/20191231160701608.html.
    [11] 王楠, 黎祺, 李军宏, 等. 世界卫生组织194个成员国疫苗纳入国家免疫规划现状[J]. 中国疫苗和免疫, 2021, 27(2): 214 – 220. doi: 10.19914/j.cjvi.2021037
    [12] World Health Organization. Immunization coverage[EB/OL]. (2021 – 06 – 15)[2022 – 03 – 03].https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
    [13] 宋丹红. 全球人乳头瘤病毒疫苗免疫规划纳入现况及世界卫生组织和联合国儿童基金会对2010 — 2019年各国HPV疫苗接种覆盖率的估计[J]. 中华医学杂志, 2021, 101(26): 2054. doi: 10.3760/cma.j.issn.0376-2491.2021.26.103
    [14] 宋祎凡, 刘晓雪, 尹遵栋, 等. 2018 — 2020年中国9~45岁女性人乳头瘤病毒疫苗估算接种率[J]. 中国疫苗和免疫, 2021, 27(5): 570 – 575.
    [15] World Health Organization. Girls aged 15 years old that received the recommended doses of HPV vaccine[EB/OL]. (2022 – 04 – 27)[2022 – 06 – 21].https://www.who.int/data/gho/data/indicators/indicator-details/GHO/girls-aged-15-years-old-that-received-the-recommended-doses-of-hpv-vaccine.
    [16] Smith MA, Winch K, Canfell K, et al. Effective HPV vaccination coverage in Australia by number of doses and two - dose spacing: What if one or two doses are sufficient?[J]. Tumour Virus Research, 2021, 11: 200216. doi: 10.1016/j.tvr.2021.200216
    [17] 陈号, 夏昌发, 由婷婷, 等. 中国女性宫颈癌负担快速上升的原因及其应对措施[J]. 中华流行病学杂志, 2022, 43(5): 761 – 765. doi: 10.3760/cma.j.cn112338-20211004-00765
    [18] World Health Organization. Cervical cancer[EB/OL]. (2022 – 02 – 22)[2022 – 03 – 03].https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
    [19] Liu YJ, Zhang Q, Hu SY, et al. Effect of vaccination age on cost - effectiveness of human papillomavirus vaccination against cervical cancer in China[J]. BMC Cancer, 2016, 16(1): 164. doi: 10.1186/s12885-016-2207-3
    [20] Wolff E, Elfström KM, Cange HH, et al. Cost - effectiveness of sex - neutral HPV - vaccination in Sweden, accounting for herd - immunity and sexual behaviour[J]. Vaccine, 2018, 36(34): 5160 – 5165. doi: 10.1016/j.vaccine.2018.07.018
    [21] Cheung TH, Cheng SSY, Hsu DC, et al. The impact and cost - effectiveness of 9 - valent human papillomavirus vaccine in adole-scent females in Hong Kong[J]. Cost Effectiveness and Resource Allocation, 2021, 19(1): 75. doi: 10.1186/s12962-021-00328-x
    [22] Mennini FS, Bonanni P, Bianic F, et al. Cost - effectiveness analysis of the nine - valent HPV vaccine in Italy[J]. Cost Effectiveness and Resource Allocation, 2017, 15(1): 11. doi: 10.1186/s12962-017-0073-8
    [23] Yaghoubi M, Nojomi M, Vaezi A, et al. Cost - effectiveness analysis of the introduction of HPV vaccination of 9 - year - old - girls in Iran[J]. Value in Health Regional Issues, 2018, 15: 112 – 119. doi: 10.1016/j.vhri.2018.03.001
    [24] 中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和宫颈病理学分会. 人乳头瘤病毒疫苗临床应用中国专家共识[J]. 中国妇产科临床杂志, 2021, 22(2): 225 – 234. doi: 10.13390/j.issn.1672-1861.2021.02.045
    [25] 徐小倩, 由婷婷, 胡尚英, 等. 全球人乳头瘤病毒疫苗接种指南制定现状的系统综述[J]. 中华医学杂志, 2021, 101(24): 1890 – 1898. doi: 10.3760/cma.j.cn112137-20210114-00130
    [26] Zou ZR, Fairley CK, Ong JJ, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost - effectiveness analysis[J]. The Lancet Global Health, 2020, 8(10): E1335 – E1344. doi: 10.1016/S2214-109X(20)30277-1
    [27] Chesson HW, Meites E, Ekwueme DU, et al. Cost - effectiveness of HPV vaccination for adults through age 45 years in the United States: estimates from a simplified transmission model[J]. Vaccine, 2020, 38(50): 8032 – 8039. doi: 10.1016/j.vaccine.2020.10.019
    [28] Wei LH, Xie X, Liu JH, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo - controlled trial with 78 - month follow - up[J]. Vaccine, 2019, 37(27): 3617 – 3624. doi: 10.1016/j.vaccine.2018.08.009
    [29] Centers for Disease Control and Prevention. HPV and Men-Fact Sheet[EB/OL]. (2022 – 01 – 03)[2022 – 03 – 03].https://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm.
    [30] Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost - effectiveness studies of human papillomavirus (HPV) vaccina-tion: 9 - valent vaccine, gender - neutral and multiple age cohort vaccination[J]. Vaccine, 2018, 36(19): 2529 – 2544. doi: 10.1016/j.vaccine.2018.03.024
    [31] Li KM, Li QL, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China[J]. Cancer, 2019, 125(7): 1030 – 1037. doi: 10.1002/cncr.32003
    [32] Kim JJ, Simms KT, Killen J, et al. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: a cost - effectiveness analysis[J]. PLoS Medicine, 2021, 18(3): e1003534. doi: 10.1371/journal.pmed.1003534
    [33] Soe NN, Ong JJ, Ma XM, et al. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost - effectiveness[J]. Human Vaccines and Immunotherapeutics, 2018, 14(12): 3010 – 3018. doi: 10.1080/21645515.2018.1496878
    [34] Grace D, Gaspar M, Rosenes R, et al. Economic barriers, evidentiary gaps, and ethical conundrums: a qualitative study of physicians' challenges recommending HPV vaccination to older gay, bisexual, and other men who have sex with men[J]. International Journal for Equity in Health, 2019, 18(1): 159. doi: 10.1186/s12939-019-1067-2
    [35] Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost - effectiveness of human papillomavirus vaccination through age 45 years in the United States[J]. Annals of Internal Medicine, 2020, 172(1): 22 – 29. doi: 10.7326/M19-1182
    [36] Linertová R, Guirado-Fuentes C, Medina JM, et al. Cost - effectiveness of extending the HPV vaccination to boys: a systematic review[J]. Journal of Epidemiology and Community Health, 2021, 75(9): 910 – 916. doi: 10.1136/jech-2020-216305
    [37] Wolff E, Elfström KM, Cange HH, et al. Cost - effectiveness of sex - neutral HPV - vaccination in Sweden, accounting for herd - immunity and sexual behaviour[J]. Vaccine, 2018, 36(34): 5160 – 5165. doi: 10.1016/j.vaccine.2018.07.018
    [38] Ye ZH, Liu ZZ, Cui ST, et al. High human papillomavirus vaccine acceptability and cost - effectiveness of the Chinese 2 - valent vaccine among men who have sex with men: a cross - sectional study in Shenyang, China[J]. Frontiers in Medicine, 2021, 8: 763564. doi: 10.3389/fmed.2021.763564
    [39] 宋晓彬, 茅范贞, 周鼒, 等. 发展中国家人乳头瘤病毒疫苗卫生经济学评价研究的系统综述[J]. 中华预防医学杂志, 2016, 50(1): 85 – 90. doi: 10.3760/cma.j.issn.0253-9624.2016.01.015
    [40] Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost - effectiveness of vaccination against oncogenic HPV types[J]. Journal of Managed Care Pharmacy, 2010, 16(3): 217 – 230. doi: 10.18553/jmcp.2010.16.3.217
    [41] 方亚, 宋晓彬, 周鼒, 等. 数学模型在HPV疫苗经济学评估中的研究进展[J]. 中国卫生统计, 2014, 31(2): 348 – 351,356.
    [42] 毕兆峰, 李亚飞, 卫飞雪, 等. 人乳头瘤病毒疫苗建模与经济学评估快速界面模型介绍及中国实例分析[J]. 中华预防医学杂志, 2019, 53(7): 744 – 751. doi: 10.3760/cma.j.issn.0253-9624.2019.07.016
    [43] Võrno T, Lutsar K, Uusküla A, et al. Cost - effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage[J]. Vaccine, 2017, 35(46): 6329 – 6335. doi: 10.1016/j.vaccine.2017.08.083
    [44] Van Minh H, My NTT, Jit M. Cervical cancer treatment costs and cost - effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study[J]. BMC Health Services Research, 2017, 17(1): 353. doi: 10.1186/s12913-017-2297-x
    [45] 马越, 柯夏童, 梁栩源, 等. 传播动力学模型在HPV疫苗经济学评价中应用[J]. 中国公共卫生, 2021, 37(12): 1742 – 1745. doi: 10.11847/zgggws1128234
    [46] 陈俊泽, 曾雁冰, 方亚. 疫苗经济学评价中的数学模型研究进展[J]. 中国卫生统计, 2016, 33(6): 1092 – 1096.
    [47] 宋晓彬, 赵勤俭, 周鼒, 等. 二价HPV疫苗接种策略的卫生经济学评估: 基于动态模型[J]. 中华预防医学杂志, 2017, 51(9): 814 – 820. doi: 10.3760/cma.j.issn.0253-9624.2017.09.008
    [48] Damm O, Horn J, Mikolajczyk RT, et al. Cost - effectiveness of human papillomavirus vaccination in Germany[J]. Cost Effec-tiveness and Resource Allocation, 2017, 15(1): 18. doi: 10.1186/s12962-017-0080-9
    [49] Keane A, Shi JF, Simms KT, et al. Health economic evaluation of primary human papillomavirus screening in urban populations in China[J]. Cancer Epidemiology, 2021, 70: 101861. doi: 10.1016/j.canep.2020.101861
    [50] Datta S, Pink J, Medley GF, et al. Assessing the cost - effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK[J]. BMC Infectious Diseases, 2019, 19(1): 552. doi: 10.1186/s12879-019-4108-y
    [51] Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States[J]. The New England Journal of Medicine, 2008, 359(8): 821 – 832. doi: 10.1056/NEJMsa0707052
  • 加载中
表(1)
计量
  • 文章访问数:  41
  • HTML全文浏览量:  6
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-27
  • 网络出版日期:  2023-01-10

目录

    /

    返回文章
    返回